Valerio Therapeutics
C4X
Company Profile
Business description
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using two proprietary platforms: the PlatON platform and its DNA decoy mechanism of action, and the V-Body platform generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-ofconcept, a value-creating inflection point appealing to potential partners. Its pipline includes Metabolic Diseases, Immunology & Inflammatory, and Oncology.
Contact
49, Boulevard du General
Martial Valin
Paris75015
FRAT: +33 145587600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
25
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,018.80 | 0.80 | -0.01% |
| CAC 40 | 8,168.15 | 56.13 | 0.69% |
| DAX 40 | 24,490.41 | 139.29 | 0.57% |
| Dow JONES (US) | 48,367.06 | 94.87 | -0.20% |
| FTSE 100 | 9,940.71 | 74.18 | 0.75% |
| HKSE | 25,630.54 | 224.06 | -0.87% |
| NASDAQ | 23,419.08 | 55.27 | -0.24% |
| Nikkei 225 | 50,339.48 | 187.44 | -0.37% |
| NZX 50 Index | 13,548.42 | 0.29 | 0.00% |
| S&P 500 | 6,896.24 | 9.50 | -0.14% |
| S&P/ASX 200 | 8,714.30 | 0.50 | -0.01% |
| SSE Composite Index | 3,962.24 | 2.88 | -0.07% |